Abstract: Technologies used for high throughput screening (HTS) at G protein coupled receptors (GPCRs) comprise two major approaches; those generally conducted measuring signal intensity changes using a microtiter plate format, and those measuring cellular protein redistribution via imaging-based analysis systems. Several homogeneous assays, i.e. those without wash and fluid phase separation steps, measure changes of second messenger signaling molecules including cAMP, Ins P 3 and calcium. Imaging based assays determined the translocation of GPCR associated proteins such as β arrestin, or internalization of the receptor labeled with fusion tags. Generally, the former assays are used in a primary screening campaign, whilst the latter are used in secondary screening and lead optimization. However, increasing use of automated confocal imaging systems and prevalence of modified cell lines has expanded use of protein redistribution assays. Finally, radiometric techniques are widely used, frequently to measure GPCR ligand binding, using a scintillation proximity assay format. In this paper, the various assay methods used for HTS at G protein coupled receptors are compared and contrasted.
against only 40-50 well-characterized GPCRs. As there are between 800-1000 genes in the human genome belonging to the GPCR superfamily, it is likely that many more GPCRs remain to be validated as drug targets. Furthermore, endogenous ligands have been identified for only 200 GPCRs, even though the human genome contains many more GPCR genes. When the sensory classes of GPCRs are excluded, many of the remaining GPCRs are 'orphan' in nature, in that no ligand or function is presently known. There is therefore, intense interest in identifying novel ligands for orphan GPCRs, both as potential therapeutics, or as pharmacological probes to refine physiological function [6] .
The primary function of GPCRs is to transduce extracellular stimuli into intracellular signals. GPCRs are a large, diverse and highly conserved class of membrane-bound proteins. On the basis of homology with rhodopsin, they possess a single, serpentine, polypeptide chain with seven transmembrane helices, comprising of three extracellular loops and three intracellular loops. The amino terminal is located extracellularly, and the carboxy terminal intracellularly. GPCRs are divided into three broad classes, based upon the similarity of the transmembrane sequences and the nature of their ligands. Class 1 includes rhodopsin-like receptors, and the ligands that activate them are biogenic amines, chemokines, prostanoids, and neuropeptides. Class 2 includes secretin-like receptors, and are activated by ligands including secretin, parathyroid hormone, glucagon, calcitonin gene related peptide, adrenomedullin, calcitonin, etc. Class 3 includes metabotropic-glutamate-receptor-like and calcium sensing receptors [7] .
Agonist binding to the GPCR promotes a conformational change in the protein, specifically an ionic interchange between the 3 rd and 4 th transmembrane domain. This induces coupling of the GPCR to the G protein, initiating signaling to the cell interior. Although a diverse protein class, the diversity of GPCR pathways activated in the cell is relatively small, and often involves modulation of two membrane bound enzymes, adenylyl cyclase and phospholipase C. GPCR signaling induces coupling of the liganded receptor to a heteromeric G protein. These are composed of α, β and γ subunits, also a diverse protein group, comprising 18 Gα, 5 Gβ and 11 Gγ subunits. The GPCR/G protein interaction accelerates exchange of guanosine triphosphate (GTP) for guanosine diphosphate (GDP) on the α subunit, leading to the dissociation of the complex from the βγ subunits. The free α or βγ subunits then interact with second messengers; the precise nature of which is dependent upon the GPCR subtype, and the G protein subunits mobilized [8] .
GPCR coupling to Gα s and Gα i /o proteins activate or inhibit, respectively, adenylate cyclase, the enzyme responsible for converting adenosine triphosphate (ATP) to 3' 5' cAMP and inorganic pyrophosphate. cAMP then acts at several downstream targets including ion channels, kinases that modulate gene transcription and cell metabolism. GPCRs coupling to G α q/o proteins, alternatively, activate phosphoinositol phospholipase Cβ, which hydrolyzes phosphatidylinositol 4, 5 bisphosphate (PIP 2 ) forming sn 1, 2 diacylglycerol and inositol 1, 4, 5 trisphosphate (Ins P 3 ). Ins P 3 binds and opens endoplasmic Ins P 3 gated calcium channel, causing release of bound calcium into the cytosol. Metabolic products of Ins P 3 also modulate cellular function including inositol (1, 3, 4, 5) P 4 (Ins P 4 ), which acts to facilitate Ins P 3 , mediating calcium release synergistically [8] .
In the presence of continued agonist activation of the GPCR, signaling is attenuated by a coordinated process of desensitization, inactivation and internalization occurs, resulting in GPCR phosphorylation by specific GPCR kinases (GRKs), and subsequent association with the adapter molecule, β arrestin. This complex then initiates the internalization and recycling processes of the receptor: ligand complex [9] . The protein, β arrestin, also facilitates formation of multimolecular complexes, and provides the means by which liganded GPCRs influence numerous cell pathways. By this means, GPCRs activate interconnected pathways, including those involving MAP kinases, nonreceptor tyrosine kinases, receptor tyrosine kinases, phosphatidylinositol 3-kinases, and JNKs [10] .
In the context of assays for HTS, several aspects of GPCR signaling described above have been utilized in various assay formats. Thus, ligand binding, guanine nucleotide exchange, second messenger mobilization, ancillary protein recruitment and receptor internalization have all been used as the basis for HTS assays. In the present review, various high throughput approaches for GPCR screening are assessed and are summarized in Table (1) . Several reviews on this subject have been published, and the reader is referred to these for additional references [1] [2] [3] [4] .
Cellular Expression of GPCRs
The cell background imposes phenotypic selectivity on GPCR ligand pharmacology [11] , which implies that the cell type used to express the receptor for screening is critical. Phenotype-specific pharmacology arises from several causes. Firstly, several GPCRs, particularly those from classes 1 and 3, form dimers or higher order oligomers at the plasmamembrane. Although GPCRs dimerize early in the synthetic pathway, the addition of agonists or antagonists influences formation of higher order oligomers [12] . It is now evident that GPCR oligomer formation depends on both the cell type, as well as the ligand. [13] Secondly, ancillary proteins expressed in the cell also modulate receptor function, and therefore, ligand pharmacology. Specifically, GPCRs interact with several transmembrane and soluble proteins, collectively termed GPCR-interacting proteins or GIPs. These GIP complexes couple to the carboxy terminal of the receptor, linking GPCR activation to a diverse network of pathways termed 'receptorsomes'; the co-localization of which provides defined spatial and temporal motifs that are highly cell dependent [14] . One example of the effect of such ancillary proteins are the RAMP (receptor activity modifying proteins) class of proteins, the nature of which determines the level and pharmacology of GPCR activity. Thirdly, the cell phenotype influences the action of allosteric GPCRs ligands. Such ligands, in contrast to surmountable agonists and antagonists, act at sites additional to the ligand binding site on the GPCR. They thus modulate receptor function, while maintaining important temporal aspects of cell signaling [15] . Allosteric ligands can have high selectivity between GPCR subtypes, and may even exert actions in their own right by modulating constitutive receptor activity. Since neither all allosteric ligands block receptors similarly, nor all agonists are blocked equally, the allosteric function of the GPCR ligand also varies according to the cellular phenotype [15] . Overall, compound efficacy, previously considered to be an exclusive property of GPCR and its ligand, is now also an essential property of the cell or tissue in which the receptor is expressed [16] . These considerations highlight the importance of the choice of cell for use in screening of novel GPCR ligands. Furthermore, the ability of the phenotype to modulate cell function specifically provides a level of complexity to the pharmacology of the ligand being screened. This is one of the reasons why cell based functional assays have increased in use in HTS campaigns. Most GPCR HTS assays employ non-recombinant or recombinant stable cell lines, as opposed to native tissues, partly due to the need for a large number of clonal cells of constant phenotype in the screen. Several non-recombinant cells have the major advantage that they endogenously express GPCRs, presumably in a background appropriate to expression and function of the receptor. However, the endogenous GPCR expression levels are often too low to be successfully used in ligand binding assays, and sensitive functional assays remain the only viable option for their use in HTS. Recombinant cells, alternatively, can be constructed to express specific GPCRs in mammalian systems, such as HEK (human embryonic kidney) or CHO (chinese hamster ovary) cells. Here, the high expression levels are easily adjusted, particularly when using plasmid expression vectors harboring viral promoters. Typically, these promoters are derived from cytomegalovirus virus (CMV) or Rous sarcoma virus (RSV), and contain antibiotic resistant genes allowing for detection of positively transfected clones. Mammalian bicistronic expression vectors are often used with the advantage that there is two open reading frames from one mRNA. In some cases, particularly where cell membranes may be used in a binding assay, the GPCR is transiently expressed. This increases the speed at which cells are produced for the screen, but allows receptors to be expressed at similar levels, facilitating easier comparison between multiple receptors.
In instances where very large numbers of cells are needed as in, for example, a large cell based HTS campaign, stably transfected cells are preferred. The high expression levels of GPCRs are also optimized for several HTS assay formats, including both membrane binding and cellular functional studies. Very high level of expression of GPCRs can be attained using Baculovirus-insect expression systems. Currently, recombinant baculoviruses, where the insect cell specific promoter is replaced with a mammalian cell active expression cassette, provide very efficient gene delivery in many mammalian cell types [17] . A recent report [18] has shown simultaneous expression of multiple GPCR genes in HEK 293 or U-2 OS osteosarcoma cells, using a GPCR and a G protein chimera, coupling the receptor to a calcium response. Similar observations have been shown in Sf 9 cells, using co expression of GPCRs with the promiscuous Gα16 subunit and a luminescent protein aequorin [18] .
High levels of receptor expression, such as baculoviral recombinant techniques, also render them very useful for isolation of membranes for use in binding studies, enhancing the specific binding of the ligand. However, when such membranes are used in low assay volumes, ligand depletion may occur that will complicate analysis. Indeed, membrane binding assays may yield different pharmacological data than that derived from binding studies with whole cells, particularly since inverse agonists bind more slowly and with lower affinity to GPCRs. This can cause the membrane-based assay to miss compounds acting in this manner; an issue of high relevance, when the screen is directed at finding inverse agonists at constitutively active orphan GPCRs [11] .
HIGH THROUGHPUT LIGAND BINDING ASSAYS

Measurement of GPCR Ligand Binding
Radioisotopic labeling of GPCR ligands are widely employed in GPCR screening and utilize three general approaches [19] Firstly, saturation experiments in which the affinity of the radioligand is determined, secondly, inhibition studies in which the affinity of a competing unlabeled compound is measured and thirdly, kinetic experiments in which the association or dissociation rates of the radioligand are defined [19] . Radioligand binding assays use [ 3 H] or [ 125 I] isotopes incorporated into ligands which are then used in low, tracer, concentrations, to monitor specific binding. A competition displacement format is often used in HTS, involving a fixed concentration of radioligand, and its displacement from the GPCR by the library compound. Historically, this approach has utilized wash and filtration procedures to separate the bound ligand from the unbound material, with the residual activity measured by liquid scintillation spectrometry. This approach has the advantage that it is very quantitative in terms of ligand pharmacology, and widespread adoption of the technique over the years has resulted in the broad commercial availability of radioligands for several GPCRs. The need to minimize filtration and resultant radioactive waste has also driven adoption of a scintillation proximity assay (SPA) format. In an SPA assay, radiolabeled molecules binding to the GPCR membrane preparation activate the scintillating beads, triggering red or blue light emission. Several polystyrene beads, optimized for HTS are available such that non-specific ligand binding is reduced. These include beads with a yttrium core covered by hydrophilic coatings, or those with Wheat germ agglutinin covalently attached to the bead surface, enhancing capture cell membranes and further reducing non specific binding [20] .
A limited number of non-isotopic approaches have been developed for GPCR ligand binding assays, the majority of which employ fluorescence polarization (FP) detection. GPCR ligands labeled with fluorescent dyes, such as fluorescein or BODIPY TMR, have been used to determine binding to GPCRs via FP detection. FP is the ratio of fluorescence emissions in the vertical and horizontal planes. When fluorescent molecules are excited with polarized light, the degree to which the emitted light retains polarization, reflects the rotation that the molecule underwent between excitation and emission. Small molecules rotate rapidly, and emitted light is random with respect to the plane of emission. When bound to a large protein (such as a GPCR), the ligand rotates slowly, and the emitted light retains more of its polarization, which is measured as an increase in FP. The extent of polarization increase is linearly dependent on the extent of binding [21] . FP assays, apart from eliminating radioactivity, are homogeneous, allowing for a real-time, continuous readout of binding activity [22] . However, the approach requires the use of amounts of cell membrane or high levels of expression of GPCRs than those generally required for radioligand binding protocols [23] . Moreover, FP based assays, with few exception, are mostly restricted to peptidergic GPCR ligands, in contrast to the wide variety of isotopically labeled ligands. Fluorescence intensity distribution analysis (FIDA) allows single molecule detection that is sensitive to changes in intensity, which occurs when fluorescent ligands bind to membranes. Indeed, the approach appears to require lower GPCR expression levels than FP. When used in a confocal mode, FIDA allows the use of extremely low assay volumes to approach those volumes used in ultraHTS [24, 25] .
Measurement of Guanine Nucleotide Binding
GPCR binding assays do not easily differentiate between those compounds that bind and activate the receptor (agonists), from those that bind and occlude the receptor, preventing subsequent activation (antagonists). A radiometric binding approach used assesses GPCR activation measures of guanine nucleotide binding to the liganded GPCR [19, 26] . Agonist binding to GPCRs promotes the exchange of GDP for GTP at the a subunit of heterotrimeric GTP binding proteins (G proteins). Poorly hydrolysable GTP analogs, such as GTPγS, or its isotopic analog, [ 35 S] GTPγS, are used, to monitor the agonist-dependent activation of G proteins in membranes from cells expressing GPCRs. This technique has been widely used over the years, and a fully automated SPA assay using this technique was reported using GPCRs coupled to G α i subunit [27, 28] . Moreover, the use of GPCR-G protein fusion proteins, expressed as bifunctional polypeptides allow [
35 S] GTPγS binding assays to be developed that explore the extent of GPCR oligomerization. When used with complementary pairs of non-functional mutants that reconstitute function when co-expressed, studies can be designed that discriminate between homo and heterodimerization [29] .
Three different approaches enable measurement of [
35 S] GTPγS binding to specific Gα-subunit families: (i) co expression of G proteins and receptors in Sf9 insect cells; (ii) construction of GPCR-Gα fusions in cells; (iii) immuno-capture techniques. Immunocapture methods, notably, do not require cell engineering for co expression of receptors and G proteins or the creation of fusion constructs. De Lapp has recently reviewed a technique combining immunocapture with SPA technology [30] . This method is easily automated and allows analysis of agonist, partial agonist, antagonist and inverse agonist activity at the level of specific interactions between GPCRs and Gα subunits. However, the productivity of antibody-capture SPA requires the use of large amounts of diluted antibody for 96-well plate incubations, making antibody considerably costly [30] .
The identification of non radiometric alternatives to [
35 S] GTPγS is difficult, principally due to problems of incorporating a detectable label that does not impair G protein binding [31] . A time resolved fluorometric GTP-binding assay has been described, using a GTP analog labeled with a Europium chelate, followed by a filtration washing step [32] . Currently, however, there are few reports in the literature, relating to the use of the technique in HTS. GTP binding assays in general, provide only data at discrete intervals and are not always able to resolve the rapid kinetics of heterotrimeric G-protein signaling applications. Real time, fluorescence-based analyses of G protein and RGS-protein signaling offer some advantages in this regard. Currently, the most important fluorescence-based assay uses BODIPY-FL-GTPδS. Upon binding Gδ protein BODIPY-FL-GTPδS exhibits up to a six-fold increase in fluorescence emission at 510 nm, following excitation at 490 nm [33] .
HIGH THROUGHPUT FUNCTIONAL ASSAYS
In the last decade, the use of cell based assays to analyze GPCR ligands interactions has accelerated [34] . Although isotopically based techniques to measure ligand binding are still widely used (see above), numerous cell based assays are now in mainstream HTS use [35] . Measurement of liganded GPCR effects on cell function, as opposed to binding per se, permits characterization of compounds that modulate receptor activity in the cell environment. Thus, novel agonists are easily discerned from antagonists. Moreover, agents acting on GPCRs by other mechanisms, such as allosteric regulators or G protein activators, can be easily identified. These functional modulators, collectively, are difficult to characterize using binding methods alone [36] . Functional GPCR assays are also a prerequisite for the identification of endogenous or synthetic ligands for orphan GPCRs [1] , including those compounds acting as inverse agonists to reduce constitutive G protein coupling [38] .
Functional GPCR platforms typically utilize either reporter gene approaches, or assays monitoring the mobilization of cAMP or intracellular calcium [4] . In high throughput screening, all these approaches need to be amenable to automated fluid handling, scalable to different fluid volumes for use in high density microtiter plate formats, and generate a signal, generally free from artifactual interference. Since wash and separation steps are an impediment to automated fluid dispensing, HTS functional assays also require protocols to be homogenous.
Reporter Gene Assays to Measure GPCR Function
GPCR activation is well known to alter gene transcription [4] . Several genes contain responsive elements to second messengers, mobilized by GPCRs that can modulate gene expression, providing the basis for reporter gene assays [4] . In reporter gene assays, GPCR signal transduction is monitored using expression systems engineered with cisacting enhancer elements, DNA sequence motifs targeted by binding partners promoting gene expression and upstream of a reporter gene. These include β lactamase [39] , β galactosidase, luciferase [40] and green fluorescent protein (GFP) [41] . GPCR signaling via changes in cAMP are assayed using the CRE (cAMP response element) enhancer of gene expression, while GPCRs coupled to changes in calcium utilize the calciumsensitive AP1 (activator protein 1) or NFAT (nuclear factor of activated T cells) elements [39] . The principal advantages of reporter gene assays are the wide linearity and sensitivity of the technique, making them very suitable for detection of weak GPCR agonists, or allosteric modulators. Reporter gene assays can also be used in the extremely low assay volumes used for 1536 or 3456 microtiter plate assay formats [4, 39] . However, the potential for false positives in the assay, arising from 'off target' actions of library compound on gene transcription during prolonged incubation times, necessitates the use of numerous controls or follow up assays.
Second Messenger Assays to Measure GPCR Function
Measurement of GPCR second messengers usually involves assays to determine accumulation of cAMP [41] or calcium [42] . Intracellular changes in these second messengers are undertaken in either the broken cells following lysis or in intact cells using cell-penetrant dyes, respectively. Although spatial information is lost in such 'end point' protocols, in contrast to the imaging based assays (see below), assays of this type provide highly quantitative pharmacological information on ligands that modulate the GPCR function. Data, such as this, is important in defining the action of the novel compound and thus, the structure activity relationships of a chemical series [43] .
Accumulation of 3' 5' cAMP
Cyclic AMP, specifically 3' 5' cyclic AMP, plays an important role in many signal transduction pathways. Consequently, the intracellular levels of cAMP are tightly regulated via the activity of the adenylyl cyclase enzyme family, some of which can be activated or inhibited by G proteins subunits, mobilized by GPCR activation. Changes in the intracellular cAMP levels correlate with GPCR activation and measurement of cAMP levels, a simple functional assay for GPCR screening. There are several assays for the measurement of cAMP, including those in which the accumulation of cAMP is assessed in a homogenous assay format. These have been reviewed in detail [41] and for the sake of brevity, will not be further discussed in the present review. However, one that aspect was highlighted, is based upon β galactosidase (β Gal) enzyme fragment complementation (EFC) [44, 45] .
β Gal is an enzyme extensively used in cellular biology as a biological reporter. EFC occurs, when fragments of β gal complement in trans by intracistronic combination to form active enzyme [46, 47] . The commercial availability of numerous β gal substrates enables colorimetric, fluorescent or chemilumescent signals to be generated. In a competitive immunoassay approach, β gal EFC is now widely used for high throughput detection of cAMP [41] . Here, cAMP is chemically conjugated to a small (~5Kd) peptide fragment derived from the β gal α peptide. This conjugate complements to an inactive β gal ω peptide forming active enzyme. Steric hindrance of EFC occurs when an antibody is added to the assay that binds conjugated cAMP, such that little or no active β gal is formed. However, free cAMP generated by the cell competitively displaces the conjugated nucleotide from the antibody, allowing it to freely complement and thus generating a signal.
Accumulation of Inositol Phospholipids
Assessment of G q coupled GPCRs, is undertaken by measurement of changes in phosphoinositide phospholipase C activity. This is often done by measuring turnover of the inositol phospholipids cycle [48] , using tritiated inositol incorporated. Activation of the GPCR, increases the incorporation of the radioactive inositol in the presence of lithium. This ion uncompetitively blocks inositol monophosphate phosphatase, thereby abrogating the cycle and increasing accumulation of the tritiated isotope at the monophosphate form [48] . This approach has been recently used in conjunction with immobilized metal ion affinity and SPA techniques, to provide a homogenous platform suitable for HTS automation [49, 50] .
The measurement of the second messenger, Ins P 3 specifically, is undertaken differently, using mass assays with GLC (gas liquid chromatography), anion exchange chromatography or HPLC. These techniques, while sensitive, are not adaptable to assays requiring high throughput. The recognition that Ins P 3 binds to a specific intracellular receptor provides the basis for a radiometric competition-binding assay. Here, [ 3 H] labeled Ins P 3 is displaced from a crude preparation of the Ins P 3 receptor, using a competition radioligand binding protocol [51] . This format, again when used with SPA, is high throughput [52] , but the economics of isotopic waste disposal emanating from high volume screening, remains a significant issue.
A non-isotopic assay for Ins P 3 is now available using the ALPHAscreen technology [53] . This technique is an amplified luminescence assay that employs a donor and acceptor bead. When the donor bead is excited with light at 680nm, a photosensitizer coverts O 2 to single oxygen. When two beads are in close proximity, the single oxygen produces a chemiluminescent signal in the acceptor bead, activating bead fluorophores and amplifying the signal. In an Ins P 3 assay, the two beads are held in close proximity by a biotinylated Ins P 3 molecule, as the donor bead is coated with streptavidin, and the acceptor bead is coated with an Ins P 3 binding protein. In the absence of cell stimulation, a signal is seen. In the presence of free Ins P 3 from the cell, the donor and acceptor beads dissociate and the signal proportionally decreases [53] . Despite the advantage of ALPHAscreen approach as a non-isotopic homogeneous assay technology, the signal can be sensitive to compound quenching and ambient fluctuations in light and temperature. The ALPHAscreen Ins P 3 assay is also limited in the number of cells per well, as matrix interferences from cell lysates reduce the signal. Echelon Biosciences have recently utilized the ALPHAscreen assay format, using a binding protein that binds several inositol phosphates, including IP 2 and IP 4 . These cellular metabolites compete with a biotinylated inositol phosphate analog as described above [54] . This assay has an advantage that it detects several phosphoinositols, resulting in slower kinetics and an assay that is more easily automated. However, an extensive evaluation in HTS screens has not been reported to date.
A novel assay has been developed at DiscoveRx Corp to measure Ins P 3 , which uses a fluorescent polarization format. The Ins P 3 assay is a competitive binding assay, in which cellular Ins P3 displaces a fluorescent derivative of Ins P 3 from a specific binding protein. The assay measures changes in fluorescence polarization (FP), a single wavelength ratiometric technique, in which a fluorescent derivative of Ins P 3 is used as a tracer. The FP Ins P 3 assay is performed in crude cell lysates, thereby avoiding laborious separation and filtration steps. It is therefore important that the Ins P 3 binding protein exhibits high affinity and selectivity for the D-myo-1, 4, 5-inositol-Ins P 3 isomer, over other inositol polyphosphates. The buffer used in the Ins P 3 assay is optimized to ensure high affinity binding, and competition binding studies with several substituted inositol phosphates demonstrate that the Ins P 3 binding protein is specific for the D-myo inositol 1, 4, 5 Ins P 3 isomer.
Accumulation of Calcium
Measuring changes in intracellular calcium, mobilized by GPCR activation, provide a highly sensitive assay technique to measure ligand function. [55] Platforms such as the fluorometric imaging plate reader (FLIPR) or functional drug screening system (FDSS) are used with dyes compatible with HTS applications, generally the fluorescent calcium sensitive dyes, Fluo-3, Fluo-4 or Calcium 3 [56, 57] . When bound to calcium, enhancements of 5-10 fold are seen between the resting cytosolic calcium levels and those induced by GPCR activation. Real time changes in the GPCR induced calcium transient signal are then determined in microtiter plate using the imaging instruments above. Recently, the assay using the FLIPR has now been miniaturized to a 1536 well format, reducing the cost of such assays [58] .
The sensitivity of the technique is such that functional studies using calcium transients are often undertaken in cells endogenously expressing the GPCR of interest. Alternatively, the technique can also be adapted to cell lines engineered to over express both the GPCR and promiscuous calcium coupling G-protein G α 15/16 [59, 60] . Other studies have been conducted using G α q proteins modified with the C-terminal amino acids, replaced with that from G α i/o, or G α s. The substitution permits appropriate receptor/G-protein recognition, and measurement of the functional response via calcium mobilization [61] . A promiscuous G αq subunit, lacking the highly conserved six amino acids amino terminal extension, yet possessing four residues of the Gαi sequence has also been reported [61] . This sequence is both palmitoylated and myristolylated, resulting in a G protein that specifically targets the plasmamembrane [61] . When co expressed with the GPCR, the functional responses of GPCRs are enhanced, increasing the sensitivity of the assay.
Although measuring calcium transients is an important HTS technique, the protocols can be time consuming, particularly, when the experimental parameters must be varied from cell to cell. Furthermore, calcium is a second messenger downstream from G α q coupled GPCR induced activation of PLC. Some compounds in the screening library may modulate intracellular calcium levels by means other than binding to the receptor; or may alter dye fluorescence, resulting in false positive or negative hits. Consequently, HTS platforms using the calcium sensitive bioluminescent protein, aequorin, have been developed [62, 63] . The approach utilizes the calcium ion binding property of the protein, causing in oxidation of the substrate, coelenterazine, with concomitant light emission. However, the approach requires a pre-incubation period of between four hours at room temperature or 18 hours at 4°C, prior to the addition of test compounds. The length of the incubation may also depend on the cell line and GPCR type.
PROTEIN REDISTRIBUTION ASSAYS
Measurement translocation of GPCR and/or associated proteins employ clonal cells expressing the GPCR of interest, labeled with a suitable fluorescent protein. Activation of the receptor causes redistribution of the label, which is monitored by automated confocal systems and analyzed by imaging algorithms [64] . Analogous experiments are undertaken in fixed cells, in which the proteins are visualized by immunostaining techniques. Here, antibodies are used that recognize either the native protein or an epitope tag fused to the protein. In either of these assays approaches, spatial information on the proteins after pathway activation is derived, and in the case of intact cell studies, temporal data may also obtained [64] .
Direct visualization of GPCR internalization, a ubiquitous property of GPCRs, occurs as part of the processes of receptor desensitization and inactivation [7] . The technique is facilitated by tagging the receptor with a fluorescent biomarker, generally, green fluorescent protein (GFP) [65] . Upon agonist activation, the GPCR-GFP fusion protein moves from the plasma membrane to internalized recycling compartments, forming intense bright spots [65] . Automated image capture and quantification of these trafficking events permits screening for both natural and surrogate receptor agonists [66] . Although a seemingly straightforward approach, issues are frequently presented including inappropriate targeting of the GPCR-GFP construct to the plasma membrane, and/or high levels of internalized receptor under basal conditions due to constitutive recycling. Furthermore, the pharmacological properties of a GPCR can be altered by the presence of a GFP-tag. Functional cell based GPCR assays also require labels attached to the GPCR or ancillary protein that do not affect function, yet possess sufficient sensitivity such that the GPCR is not required to be over expressed. Due to the relatively low quantal yield of fluorophores, the use of several fluorescent proteins is limited. Immunostaining procedures whilst sensitive, are highly dependent upon the quality of the antibodies used, and the immunostaining protocols can be lengthy and cumbersome for automation.
A strategy focused on the internalization pathway, exploits the acidic nature of the endosomal recycling compartments [67] . The pH-sensitive cyanine dye CypHer 5 is non-fluorescent at pH 7.4 and brightly fluorescent in acidic environments. This approach utilizes a small amino-terminal epitope tag on the GPCR, recognized by a CypHer 5 conjugated antibody. Binding of the antibody to cell surface GPCRs fails to produce a fluorescence signal, and upon ligand-dependent internalization to endosomal compartments, intensely bright fluorescence spots of CypHer 5 are observed [67] .
Monitoring cellular translocation of proteins participating in the GPCR desensitization/internalization cycle, specifically β arrestins has been developed as an assay format [68] . This approach monitors the change in distribution of a β-arrestin-GFP construct, from a diffuse intracellular localization to aggregated pit-like compartments, as a consequence of ligand-dependent internalization. Theoretically, the technique is applicable across GPCRs, and may overcome limitations associated with direct GPCR tagging [69] . Provided some degree of plasma membrane localization of the GPCR of interest is achieved, β arrestins translocation follows only those receptors committed towards the internalization pathway, offering a high signal-noise ratio [69] . β Arrestin translocation has also been monitored using bioluminescence energy transfer (BRET), in which a luciferase donor protein transfers energy to a green fluorescent protein [70] . In this assay, the green fluorescent protein is fused to arrestin and the GPCR to the luciferase, and translocation of the arrestin to the vicinity of the GPCR induces BRET and thus, a signal [70] . Indeed, biophysical techniques involving resonance energy transfer, namely FRET (fluorescence resonance energy transfer) or BRET enable monitoring of the formation of GPCR/protein complexes in living cells, in real-time [71] . Both FRET and BRET can be detected by microscopy, scanning spectroscopy or a suitable plate reader capable of sequential or simultaneous detection of filtered light emitted within two distinct wavelength windows. Microscopy is often used for detecting FRET, being most suitable for studies involving photobleaching. In contrast, microscopy is rarely used to detect BRET, with the majority of studies utilizing plate reading instrumentation. BRET assays have recently been modified using β arrestin mutants [71] . Here, the BRET2 signal is enhanced, using a phosphorylation independent mutant or β arrestin mutants deficient in their ability to interact with clathrin coated vesicles. Since both mutants, dissociate slowly from the GPCR, the BRET signal is enhanced, markedly improving the assay signal and allowing it to be adapted as an HTS tool.
Alternatively, weakly interacting β Gal α and ω deletion mutants are fused to the interacting G protein: β arrestins. After enrichment by FACS analysis, clones are identified with low background expression of β Gal activity, but with a ligand dependent increase in enzyme activity, reflecting ligand induced association. Since the signal is generated by enzymatic amplification, over expression of labeled proteins is not necessary, and the cellular environment not grossly perturbed. Collectively, the approach appears suitable as an HTS system for detection of GPCR agonists or antagonists, and configured to perform in 384 well microtiter plates [72] . The assay exhibits agonist potencies similar to those detected in other GPCR assays and is capable of detecting receptor inhibitors with precision characteristics appropriate to HTS.
OTHER GPCR SCREENING ASSAYS
Melanophore cells derived from the neural crest of Xenopus laevis have been developed as a highly sensitive system for GPCR screening, since GPCR activation results in dispersion of the pigment melanin [73] . This occurs irrespective of whether adenylyl cyclase or phospholipase C is activated, whereas inhibition of activation results in aggregation, causing the cells to lighten in color. The sensitivity of the assay is such that in transiently expressed systems, constitutive activity of the GPCR can be determined, and the activity of inverse agonists readily determined. When use in conjunction with mutations of the GPCR that induce constitutive activity, such as the CART (constitutive active receptor technology) approach [74] , it can provide a very simple means to assess novel ligands interacting at orphan GPCRs, as well as compounds that allosterically regulate GPCR activation.
There are several other assay technologies now emerging for use in HTS at GPCRs. Although space limitations do not permit full evaluation of each, several are described for the sake of completeness. Cellular dielectric spectroscopy is a label free analysis system, in which changes in radio frequency spectrometry and bioimpedance exhibit a characteristic pattern when GPCRs are activated by an agonist. Potentially, this may provide a generic assay for GPCRs, without the need for chimeric or promiscuous G proteins and without the incorporation of radiometric of fluorometric detection systems. Other analytical techniques to measure ligand binding to membrane receptors such as acoustic, optical surface plasmon resonance biosensing, sedimentation, isothermal titration calorimetry and differential scanning calorimetry are now emerging. These have been recently reviewed by Cooper [76] .
SUMMARY
Functional analysis of GPCR responses is a common approach for high throughput screening of libraries of compounds. Measurement of second messengers (cAMP, Ins P 3 or calcium) is readily achieved using homogeneous assays requiring neither radiometric techniques nor heterogeneous assay formats. Moreover, all these assays can be automated for robotic fluid dispensing. Other assay formats measure GPCR activation, using the redistribution of labeled protein, (β arrestin or receptor). These assays tend to have lower throughput and are applicable to many GPCR classes. Nonetheless, the ease and robustness of radioligand binding assays, as well as the limited non-radiometric alternatives, will ensure that isotopic techniques will also continue to be used. In practice, it is likely that a combination of all these HTS assay formats will be employed in compound identification, optimization and elucidation of mechanism of action.
